Related references
Note: Only part of the references are listed.Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'
N. Harbeck et al.
ANNALS OF ONCOLOGY (2022)
A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone
Monika D. Polewski et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2022)
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
Melanie Royce et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N. Harbeck et al.
ANNALS OF ONCOLOGY (2021)
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
Torsten O. Nielsen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
UK NEQAS ICC & ISH Ki-67 Data Reveal Differences in Performance of Primary Antibody Clones
Suzanne Parry et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2021)
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R. D. Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology
Eleftherios P. Mamounas et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories
Emina E. Torlakovic et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2017)
Utility of the CPS plus EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy
Frederik Marme et al.
EUROPEAN JOURNAL OF CANCER (2016)
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment
Oleg Gluz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer
Charlotte Roach et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2016)
Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small Cell Lung Cancer
Therese Phillips et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2015)
Principles of Analytic Validation of Immunohistochemical Assays Guideline From the College of American Pathologists Pathology and Laboratory Quality Center
Patrick L. Fitzgibbons et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
